Acorda Therapeutics Inc. on Friday said it would discontinue development of its Plumiaz epilepsy drug as continuing trials didn’t produce the data necessary to refile the new drug application with federal regulators.

Acorda said clinical trial data didn’t demonstrate the nasal therapy’s bioequivalence to Diastat—a rectal gel form of diazepam—required for resubmission to the U.S. Food and Drug Administration. The therapy was being studied for the treatment of seizure clusters in people with epilepsy.

Acorda said the data demonstrated “unexpectedly lower nasal mucosa absorption of diazepam” in patients with epilepsy compared to studies in healthy volunteers.

“We are very disappointed by this outcome, and for those in the epilepsy community who experience seizure clusters,” Chief Executive Ron Cohen said.

He said the company will continue to focus on development of its other high potential pipeline programs, including treatments for Parkinson’s disease and post-stroke walking difficulty.